We studied retrospectively tumor samples of 83 Saudi metastatic CRC patients for KRAS mutations in codon 12 and codon 13, to evaluate the relevance of KRAS mutation positive colorectal cancers with metastatic sites. KRAS mutation was observed in 42.2% (35/83) patients with CRC. The most common ...
However,mutations were more prevalent in colon cancer withmutations than in rectal cancer (75.0% vs 28.6%, respectively, p = 0.004). The negative predictive value of the IHC analysis for predictingamplification reached to 98.39%, while the positive predictive value reached only 50%. Overall,...
Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN KRAS mutation: from undruggable to druggable in cancer Lamei Huang1, Zhixing Guo1, Fang Wang1 and Liwu Fu1 ✉ Cancer is the leading cause of death worldwide, and its treatment and outcomes have been ...
Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy Purpose;Activating mutation of the KRAS oncogene is an established negative predictor for anti-epidermal growth factor receptor (anti-EGFR) therapies in me... ST Kim,KH...
The NCCN Colon/Rectal Cancer Panel believes that RAS mutation status should be determined at diagnosis of stage IV disease. Patients with any known RAS mutation should not be treated with either cetuximab or panitumumab....
5]Prior I.A. Hood F.E.HartleyJ.L. The frequency ofRasmutations in cancer[J] . Cancer Res...
KRAS mutation in metastatic colorectal cancer predicts resistance to anti–epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab or panitumumab). It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer patients independent of anti-EGFR ...
https://www.cancer.org/cancer/colon-rectal-cancer/treating/targeted-therapy.html [3]FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation | FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combi...
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 y
KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann. Surg. Oncol. 17, 1168–1176 (2010). Article PubMed Google Scholar Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012...